Glucocorticoid-Induced Osteoporosis

被引:238
|
作者
Buckley, Lenore [1 ]
Humphrey, Mary B. [2 ]
机构
[1] Yale Sch Med, 300 Cedar St,POB 208831, New Haven, CT 06520 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
关键词
BONE-MINERAL DENSITY; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; ORAL CORTICOSTEROIDS; BREAST-CANCER; PREVENTION; RISK; PLACEBO;
D O I
10.1056/NEJMcp1800214
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For the past month, a 75-year-old woman with polymyalgia rheumatica has received prednisone at a dose of 20 mg daily. The treatment plan is to try to taper the dose to 5 mg daily within 6 months. Given typical durations of treatment, the expectation is that she will continue to receive prednisone for 2 years. She is otherwise healthy and has no personal or family history of fracture. She does not smoke or drink alcohol. Her height is 168 cm, and she weighs 68 kg. Her serum 25-hydroxyvitamin D level is 30 ng per milliliter (74 nmol per liter). Her bone mineral density T score is -1.2 at the femoral neck. What would you advise to prevent glucocorticoid-induced osteoporosis and fracture?
引用
收藏
页码:2547 / 2556
页数:10
相关论文
共 50 条
  • [1] Management of glucocorticoid-induced osteoporosis
    Messina, Osvaldo D.
    Vidal, Luis Fernando
    Vidal, Maritza Vidal
    Bultink, Irene E. M.
    Raterman, Hennie G.
    Lems, William
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (04) : 793 - 804
  • [2] Glucocorticoid-induced Osteoporosis
    Whittier, Xena
    Saag, Kenneth G.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (01) : 177 - +
  • [3] Treatment options for glucocorticoid-induced osteoporosis
    Chiodini, Iacopo
    Merlotti, Daniela
    Falchetti, Alberto
    Gennari, Luigi
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) : 721 - 732
  • [4] Management of Glucocorticoid-Induced Osteoporosis
    Rizzoli, R.
    Adachi, J. D.
    Cooper, C.
    Dere, W.
    Devogelaer, J. P.
    Diez-Perez, A.
    Kanis, J. A.
    Laslop, A.
    Mitlak, B.
    Papapoulos, S.
    Ralston, S.
    Reiter, S.
    Werhya, G.
    Reginster, J. Y.
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (04) : 225 - 243
  • [5] Management of glucocorticoid-induced osteoporosis
    Compston, Juliet
    NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (02) : 82 - 88
  • [6] Glucocorticoid-Induced Osteoporosis and Osteonecrosis
    Weinstein, Robert S.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (03) : 595 - +
  • [7] Prevention of glucocorticoid-induced osteoporosis
    van Brussel, M. S.
    Bultink, I. E. M.
    Lems, W. F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 997 - 1005
  • [8] Glucocorticoid-induced osteoporosis: an update
    Compston, Juliet
    ENDOCRINE, 2018, 61 (01) : 7 - 16
  • [9] Glucocorticoid-induced osteoporosis in men
    Adler, R. A.
    Hochberg, M. C.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (06) : 481 - 484
  • [10] Glucocorticoid-induced osteoporosis
    den Uyl, D.
    Bultink, I. E. M.
    Lems, W. F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (05) : S93 - S98